Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPM System in Chronic Heart Failure
NCT05978518Phase 3Recruiting
- Sponsor
- Analog Devices, Inc.
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by Analog Devices, Inc. Primary endpoints: Admission rate at 7 months, Readmission rate at 7 months and 4 more. Started Jul 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05978518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978518.